This paper reviews the literature about first‐line therapies for H. pylori infection in recent
years. First‐line therapies are facing a challenge because of increasing treatment failure …

Helicobacter pylori infection still represents a major health issue, especially in developing
countries, with an estimate of 4 billion of infected subjects in 2015. The increase of antibiotic …

Helicobacter pylori (H. pylori) is a prevalent, worldwide, chronic infection. Choice of
treatment can be modified according to antibiotic-resistance rates of H. pylori. The ideal …

This review summarizes important studies regarding H. pylori therapy published from April
2013 to April 2014. The main themes that emerge are assessing the efficacy of standard …

Helicobacter pylori is a highly successful bacterium with a high global prevalence and the
infection carries significant disease burden. It is also becoming increasingly difficult to …

Triple therapy, consisting of two antibiotics, clarithomycin and amoxicillin or metronidazole in
combination with a proton pump inhibitor (PPI) has become the first-line option for infection …

ABSTRACT Introduction: Eradication of Helicobacter pylori (H. pylori) becomes more
challenging due to increasing antimicrobial resistance. Consequently, the performance of …

Background Helicobacter pylori infection is still frequent in the community and all infected
subjects should be offered an eradication therapy. Nowadays physicians have to face the …

A new treatment strategy is needed, as the efficacy of triple therapy containing clarithromycin—
the current standard treatment for Helicobacter pylori infection—is declining. Increasing …

Helicobacter pylori (H. pylori) is a major human pathogen associated with significant
morbidity and mortality. However, after decades of efforts, treatment of H. pylori remains a …